Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition(s):Lambert-Eaton Myasthenic SyndromeLast Updated:July 9, 2019No longer available
Hide Studies Not Open or Pending
Condition(s):Lambert-Eaton Myasthenic SyndromeLast Updated:July 9, 2019No longer available
Condition(s):Lambert-Eaton Myasthenic Syndrome; Congenital Myasthenic SyndromeLast Updated:April 11, 2022Approved for marketing
Condition(s):Lambert Eaton Myasthenic SyndromeLast Updated:October 30, 2019No longer available
Condition(s):Multiple Sclerosis; FatigueLast Updated:December 17, 2007Completed
Condition(s):Multiple SclerosisLast Updated:February 21, 2011Completed
Condition(s):Atrial FibrillationLast Updated:March 20, 2024Not yet recruiting
Condition(s):Lambert-Eaton Myasthenic SyndromeLast Updated:March 25, 2015Completed
Condition(s):Postoperative Atrial FibrillationLast Updated:March 15, 2019Completed
Condition(s):COVID-19Last Updated:September 5, 2021Completed
Condition(s):Drug-induced QT Prolongation; Pharmacokinetics; PharmacodynamicsLast Updated:June 8, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.